Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Etonogestrel · Nexplanon, ORG-3236

Small molecule · Agonist of progesterone receptor (PGR) · developed by Organon

Approved FDA, Jul 2006
OGN Developer
2 Registered trials

What is Etonogestrel?

Etonogestrel is a synthetic progestin, a form of the female sex hormone progesterone. It binds cytoplasmic progesterone receptors in the reproductive system, activating progesterone receptor-mediated gene expression, which inhibits luteinizing hormone release and ovulation and alters cervical mucus and the endometrium. It is studied in benign prostatic hyperplasia and menstrual symptoms.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Nexplanon, ORG-3236
Drug type
Small molecule
Targets
progesterone receptor (PGR)
Mechanism
Agonist of progesterone receptor (PGR)
Pathways
progesterone receptor-mediated gene expression, LH release inhibition (negative feedback), ovulation suppression, cervical mucus viscosity, endometrial alteration
Therapy area
Renal & urology
Developer
Organon (OGN)
FDA status
Approved as Nexplanon (July 17, 2006), NDA021529 · FDA label
UNII
304GTH6RNH

✅ FDA-approved uses

From the indications section of the FDA label (version of May 28, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00651807 Phase 2 Benign Prostatic Hyperplasia (BPH) Terminated OGN
NCT06775626 Early Phase 1 Menstrual Symptoms Suspended OGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Benign Prostatic Hyperplasia (BPH)Menstrual Symptoms

Other drugs acting on PGR

More from Organon

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the OGN page.

Follow OGN, the company behind Etonogestrel

See OGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

OGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.